William Blair analyst Matt Larew downgraded MaxCyte (MXCT) to Market Perform from Outperform following the earnings report. The company reported a miss and guidance reduction in a strong bioprocessing tools tape, the analyst tells investors in a research note. The firm attributes the miss to MaxCyte’s customer exposure and less visible revenue profile. William Blair believes the company’s visibility seems lower than peers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.